Drug Profile
Research programme: next-generation Wnt signalling pathway inhibitors - Eisai/Verastem Oncology
Latest Information Update: 11 May 2018
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; Verastem
- Developer Eisai Co Ltd; Verastem Oncology
- Class Small molecules
- Mechanism of Action Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Cancer
Most Recent Events
- 03 May 2018 Verastem is now operating as Verastem Oncology
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA